Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by Deutsche Bank AG

Deutsche Bank AG grew its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 9.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 261,363 shares of the biotechnology company’s stock after purchasing an additional 22,412 shares during the quarter. Deutsche Bank AG’s holdings in Blueprint Medicines were worth $22,796,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in BPMC. DAFNA Capital Management LLC increased its stake in Blueprint Medicines by 23.0% in the fourth quarter. DAFNA Capital Management LLC now owns 149,763 shares of the biotechnology company’s stock valued at $13,062,000 after purchasing an additional 28,000 shares during the last quarter. Brevan Howard Capital Management LP increased its stake in shares of Blueprint Medicines by 48.5% during the 4th quarter. Brevan Howard Capital Management LP now owns 17,751 shares of the biotechnology company’s stock valued at $1,548,000 after acquiring an additional 5,794 shares during the last quarter. Balyasny Asset Management L.P. lifted its holdings in shares of Blueprint Medicines by 90.7% during the 4th quarter. Balyasny Asset Management L.P. now owns 102,486 shares of the biotechnology company’s stock worth $8,939,000 after acquiring an additional 48,736 shares during the period. Bayesian Capital Management LP acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth approximately $1,620,000. Finally, Ameriprise Financial Inc. boosted its position in shares of Blueprint Medicines by 4.2% in the fourth quarter. Ameriprise Financial Inc. now owns 338,115 shares of the biotechnology company’s stock worth $29,489,000 after acquiring an additional 13,501 shares during the last quarter.

Blueprint Medicines Price Performance

BPMC stock opened at $97.51 on Thursday. The firm has a market cap of $6.30 billion, a P/E ratio of -90.29 and a beta of 0.83. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. Blueprint Medicines Co. has a 1 year low of $73.04 and a 1 year high of $121.90. The stock has a 50-day simple moving average of $89.12 and a 200-day simple moving average of $94.07.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The firm had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. During the same period in the previous year, the business posted $1.40 earnings per share. Blueprint Medicines’s revenue for the quarter was up 55.5% on a year-over-year basis. On average, equities analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Morgan Stanley initiated coverage on shares of Blueprint Medicines in a research report on Thursday, March 20th. They set an “equal weight” rating and a $100.00 price target for the company. HC Wainwright restated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, May 2nd. Wolfe Research began coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. lifted their target price on Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Finally, Scotiabank started coverage on Blueprint Medicines in a research note on Friday, March 7th. They set a “sector outperform” rating and a $150.00 price target for the company. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Blueprint Medicines has a consensus rating of “Moderate Buy” and a consensus target price of $126.56.

Insider Activity

In related news, insider Ariel Hurley sold 3,203 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the completion of the transaction, the insider now owns 18,270 shares of the company’s stock, valued at approximately $1,692,167.40. This represents a 14.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Christina Rossi sold 2,274 shares of the firm’s stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $101.75, for a total value of $231,379.50. Following the sale, the chief operating officer now owns 66,992 shares of the company’s stock, valued at approximately $6,816,436. This trade represents a 3.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,503 shares of company stock worth $1,027,931 over the last ninety days. Corporate insiders own 4.21% of the company’s stock.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.